|
Our lead cancer technology platform, OncoVEXGM-CSF is
a first-in-class oncolytic, or cancer destroying virus, that
works by replicating and spreading within solid tumors (leaving
healthy cells unaffected), thereby causing cancer cell death
and stimulating the immune system to destroy un-injected metastatic
deposits. Both modes of action have been clearly validated in
the clinic, where multiple patients with metastatic disease progressing
at enrollment have been declared disease free.
In May 2009 the Company commenced a Phase III study in melanoma
with OncoVEXGM-CSF, following
unprecedented Phase II results and following agreement with the
FDA on the design of the pivotal study. In September 2009 the
Company agreed a further SPA agreement with the FDA for a Phase
III study in Head and Neck cancer.
Our second program is a vaccine for genital herpes, ImmunoVEXHSV2,
which provides complete protection in animal models of the disease.
The vaccine has been authorized to commence clinical testing
in the UK.
|
